Business
IDEAYA Biosciences Appoints Michael White, Ph.D., as Chief Scientific Officer
- Former Chief Scientific Officer and Head of Tumor Biology at Pfizer will lead IDEAYA's research organization as Chief Scientific Officer - Over twenty-year
About this update from Ideaya Biosciences, Inc.
[{"type":"text","content":"- Former Chief Scientific Officer and Head of Tumor Biology at Pfizer will lead IDEAYA's research organization as Chief Scientific Officer\n - Over twenty-year academic career at UT Southwestern and recipient of the inaugural Outstanding Investigator's Award from the National Cancer Institute\n\n\nSOUTH SAN FRANCISCO, Oct. 18, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that Michael White, Ph.D., will join the company as its Chief Scientific Officer, effective November 1, 2021. \n\n \n \n \n \n \n \n\n \n\"We are thrilled to welcome Dr. White, and we believe his deep industry experience as CSO and Head of Tumor Biology at Pfizer, and extensive knowledge in cancer biology developed during a prolific academic career at UT Southwestern, will enable IDEAYA to extend its position as the industry leader in the emerging field of synthetic lethality. Under Dr. White's leadership we will continue to enhance IDEAYA's synthetic lethality platform and advance our next generation synthetic lethality pipeline, including in biomarker populations beyond HRD, such as MTAP, as well as utilizing both small molecule inhibitor and protein degrader drug discovery approaches,\" said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences.\n\"I am excited to join IDEAYA to help advance the company's strategic vision to discover and develop potential first-in-class and best-in-class synthetic lethality-based precision therapies for oncology. This emerging realm of precision medicine holds considerable potential to deliver new treatments for cancer patients with unmet need, particularly for those harboring disease that emerges from loss-of-function genetic alterations that are otherwise undruggable. A prominent example is MTAP-deletion, where IDEAYA is well-positioned to be an industry leader with continued advancement of the potential best-in-class Phase 1 MAT2A inhibitor IDE397 and potential novel synthetic lethality combinations,\" said Dr. Michael White. \nDr. White formerly served as Chief Scientific Officer and Head of Tumor Biology at Pfizer, Inc., where he led cross-disciplinary groups to build an oncology small-molecule pipeline focused on first-in-class therapies, ...